May 20 (Reuters) - Marker Therapeutics Inc MRKR.O:
MARKER THERAPEUTICS REPORTS THAT LYMPHODEPLETION IMPROVES THE EXPANSION AND PERSISTENCE OF MULTI-ANTIGEN RECOGNIZING T CELLS IN PATIENTS WITH LYMPHOMA
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.